An Open-Label Randomized Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of 2019 Novel Coronavirus Disease (COVID-19)
Latest Information Update: 26 Mar 2025
At a glance
- Drugs Isoquercetin (Primary)
- Indications COVID 2019 infections; COVID-19 respiratory infection
- Focus Therapeutic Use
Most Recent Events
- 24 Mar 2025 Status changed from not yet recruiting to withdrawn prior to enrolment, since it could not get started.
- 26 Aug 2021 New trial record
- 20 Aug 2021 Planned End Date changed from 1 May 2021 to 1 Jun 2023.